The company's strategy focuses on driving profitable growth through four primary pillars: organic growth from commercial activities including six FDA-approved specialty plasma-derived products (KEDRAB, CYTOGAM, GLASSIA, WINRHO SDF, VARIZIG, HEPAGAM B), new business development and M&A opportunities, plasma collection expansion, and development of additional product candidates. Kamada balances commercial stage profitability with innovative pipeline advancement in specialty plasma therapeutics.
Cyborg Score Rationale
Kamada demonstrates solid fundamentals with FDA-approved products generating commercial revenue, profitability growth (35% EBITDA increase YoY in 9M 2025), and clear strategic pillars for expansion. The company faces geopolitical risks from Israeli operations but maintains global supply resilience and positive revenue guidance.
Top Insights
Nine-month 2025 revenue reached $135.8 million, up 11% YoY with adjusted EBITDA of $34.2 million, up 35% YoY, supporting full-year revenue guidance of $178 million
The company is expanding plasma collection operations with three operating centers in the United States (Beaumont, Houston, San Antonio, Texas) to support revenue growth through plasma sales and hyper-immune plasma demand
The lead product candidate is inhaled AAT for AAT deficiency treatment, with the company continuing to progress the InnovAATe Phase 3 clinical trial
FIMI Opportunity Funds (Israeli private equity) is the controlling shareholder with approximately 38% beneficial ownership
Named Competitors
Glassia (AAT therapy) — Licensed from Kamada for US/major markets distribution
Specialty plasma products — Global plasma therapeutics company
Recent Developments
(March 2025) Obtained tax ruling from Israel Tax Authority enabling reduced withholding tax rates for international shareholders on special dividend distributions
(November 2025) Initiated post-marketing study evaluating CYTOGAM's role in reducing late CMV disease risk in high-risk kidney transplant recipients
(October 2025) Raised full-year 2025 profitability guidance based on strong Q3 performance with 13% YoY revenue growth
Open the full interactive Kamada Ltd. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.